【摘要】 目的 ：本荟萃分析是评估CD133高水平表达与肝细胞癌的临床病理及预后相关性的一个最新分析。方法 ：在PubMed、EMBASE、the Cochrane Library、中国CNKI和万方数据库中检索了截至2022年8月1日的CD133在肝细胞癌中的研究。使用RevMan5.3软件和Stata 13.0软件进行统计分析。结果 ：共确定了25项研究，涉及2700名患者。HCC患者CD133的高表达水平表明多灶性肿瘤的发生率相对较高（P=0.03），肿瘤分化等级较低，肿瘤分期较晚，肝硬化发生率相对较高，淋巴结转移的发生率明显较高，神经侵犯的发生率明显较高，脉管癌栓的发生率明显较高。此外，CD133的表达也与总生存期和无病生存期的明显恶化有关。结论 ：肝细胞癌中CD133的高表达与较差的临床病理表现和较差的预后相关，为以后CD133高表达相关的上下游靶点药物的研发提供了理论支持。更多还原

【Abstract】 Objective This meta-analysis evaluates the correlation between CD133 expression and the clinic-pathological features and prognosis of patients with hepatocellular carcinoma. Method Until 1st February 2021, PubMed, EMBASE, the Cochrane Library, Chinese CNKI and Wan Fang databases were searched for studies of CD133 in hepatocellular carcinoma(HCC). RevMan5.3 software and Stata 13.0 software were used for statistical analyses. Results A total of 25 studies involving 2700 patients were identified. The high level of CD133 expression in HCC patients indicated a relatively higher incidence of multifocal tumor, lower tumor differentiation grade, more advanced tumor stage, a relatively higher incidence of liver cirrhosis,a significantly higher incidence of lymph node metastasis, a significantly higher incidence of neural invasion and a significantly higher incidence of lymph-vascular invasion. Additionally, CD133 expression was associated with worse overall survival(OS)and disease-free survival(DFS). Conclusion High level of CD133 expression in hepatocellular carcinoma was related with more aggressive clinical-pathological features and prognosis, suggesting another potentially feasible CD133-based targeted spot. It is necessary to focus future studies on its specific mechanism of carcinogenesis and the development of therapies that target CD133.更多还原